{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:29:21Z","timestamp":1768523361308,"version":"3.49.0"},"reference-count":31,"publisher":"PAGEPress Publications","issue":"4","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Transl Myol"],"abstract":"<jats:p>This study aimed to evaluate the efficacy of a novel combination therapy, AVC (Anti-Vitiligo Cream), compared to common treatments for vitiligo. A randomized interventional study was conducted on 1,000 patients with confirmed vitiligo, aged 7\u201370 years. Participants were divided into five groups (200 patients each): oral prednisolone, Tofacitinib, Ruxolitinib, AVC (Anti-Vitiligo Cream), and AVC combined with Tofacitinib. Outcomes were assessed over two years using the Vitiligo Area Scoring Index (VASI), patient satisfaction scores, and clinical observations. AVC-based therapies (Groups 4 and 5) demonstrated superior efficacy and patient satisfaction compared to other treatments. Group 5 (AVC + Tofacitinib) achieved the highest outcomes, with a mean satisfaction score of 90 (IQR: 85\u201395) and treatment efficacy significantly higher than Group 1 (p &lt; 0.001). Regression analysis identified treatment outcomes and therapy type as significant predictors of satisfaction. AVC (Anti-Vitiligo Cream), particularly in combination with Tofacitinib, represents a groundbreaking approach for managing vitiligo, providing enhanced efficacy and patient satisfaction. These findings support the potential of AVC-based therapies as a standard treatment option.<\/jats:p>","DOI":"10.4081\/ejtm.2025.13787","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:49:17Z","timestamp":1748256557000},"source":"Crossref","is-referenced-by-count":0,"title":["A randomized interventional study that compares treatments for vitiligo and anti-vitiligo cream"],"prefix":"10.4081","volume":"35","author":[{"given":"Shahzad","family":"Shirzad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdis","family":"Miladi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"180580","doi-asserted-by":"crossref","unstructured":"Ezzedine K, Lim HW, Suzuki T et al. Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012;25:E1-13.","DOI":"10.1111\/j.1755-148X.2012.00997.x"},{"key":"180581","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol 2012;51:1206-12.","DOI":"10.1111\/j.1365-4632.2011.05377.x"},{"key":"180582","doi-asserted-by":"crossref","unstructured":"Picardo M, Dell'Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primers 2015;1:15011.","DOI":"10.1038\/nrdp.2015.11"},{"key":"180583","doi-asserted-by":"crossref","unstructured":"Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol 2008;74:701.","DOI":"10.4103\/0378-6323.45144"},{"key":"180584","doi-asserted-by":"crossref","unstructured":"Ta\u00efeb A, Picardo M; VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35.","DOI":"10.1111\/j.1600-0749.2006.00355.x"},{"key":"180585","doi-asserted-by":"crossref","unstructured":"Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol 2018;57:1157-164.","DOI":"10.1111\/ijd.14055"},{"key":"180586","doi-asserted-by":"crossref","unstructured":"Lee JH, Ju HJ, Seo JM, Almurayshid A, et al. Comorbidities in patients with vitiligo: a systematic review and meta-analysis. J Invest Dermatol 2023;143:777-789.e6.","DOI":"10.1016\/j.jid.2022.10.021"},{"key":"180587","doi-asserted-by":"crossref","unstructured":"Klisnick A, Schmidt J, Dupond JL, et al. Le vitiligo au cours des syndromes auto-immuns multiples: \u00e9tude r\u00e9trospective de 11 observations et revue de la litt\u00e9rature [Vitiligo in multiple autoimmune syndrome: a retrospective study of 11 cases and a review of the literature]. Rev Med Interne 1998;19:348-52.","DOI":"10.1016\/S0248-8663(98)80107-0"},{"key":"180588","doi-asserted-by":"crossref","unstructured":"Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol 1976;94:43-50.","DOI":"10.1111\/j.1365-2133.1976.tb02268.x"},{"key":"180589","doi-asserted-by":"crossref","unstructured":"Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol 2019;155:929-38.","DOI":"10.1001\/jamadermatol.2019.0696"},{"key":"180590","doi-asserted-by":"crossref","unstructured":"Kandaswamy S, Akhtar N, Ravindran S, et al. Phototherapy in vitiligo: assessing the compliance, response and patient's perception about disease and treatment. Indian J Dermatol 2013;58:325.","DOI":"10.4103\/0019-5154.113944"},{"key":"180591","doi-asserted-by":"crossref","unstructured":"Faraj S, Kemp EH, Gawkrodger DJ. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol 2022;207:27-43.","DOI":"10.1093\/cei\/uxab002"},{"key":"180592","doi-asserted-by":"crossref","unstructured":"Chang WL, Ko CH. The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications. Cells 2023;12:936.","DOI":"10.3390\/cells12060936"},{"key":"180593","doi-asserted-by":"crossref","unstructured":"Bharti N, Banerjee R, Achalare A, Kasibhatla SM, Joshi R. Estimation of genetic variation in vitiligo associated genes: Population genomics perspective. BMC Genom Data 2024;25:72.","DOI":"10.1186\/s12863-024-01254-6"},{"key":"180594","doi-asserted-by":"crossref","unstructured":"Spritz RA, Andersen GH. Genetics of vitiligo. Dermatol Clin 2017;35:245-55.","DOI":"10.1016\/j.det.2016.11.013"},{"key":"180595","doi-asserted-by":"crossref","unstructured":"Inoue S, Suzuki T, Sano S, Katayama I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci 2024;113:86-92.","DOI":"10.1016\/j.jdermsci.2023.12.008"},{"key":"180596","doi-asserted-by":"crossref","unstructured":"Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol 2021;12:790125.","DOI":"10.3389\/fimmu.2021.790125"},{"key":"180597","doi-asserted-by":"crossref","unstructured":"Lee H, Cowan TL, Daniel BS, Murrell DF. A review of JAK and IL-23 inhibitors to treat vitiligo. Australas J Dermatol 2023;64:204\u201312.","DOI":"10.1111\/ajd.14001"},{"key":"180598","doi-asserted-by":"crossref","unstructured":"Karagaiah P, Schwartz RA, Lotti T, et al. Biologic and targeted therapeutics in vitiligo. J Cosmet Dermatol 2023;22:64-73.","DOI":"10.1111\/jocd.14770"},{"key":"180599","doi-asserted-by":"crossref","unstructured":"Grossmann MC, Haidari W, Feldman SR. A review on the use of topical ruxolitinib for the treatment of vitiligo. J Drugs Dermatol 2023;22:664-67.","DOI":"10.36849\/JDD.7268"},{"key":"180600","doi-asserted-by":"crossref","unstructured":"Tavoletti G, Avallone G, Conforti C, et al. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol 2023;37:2222-30.","DOI":"10.1111\/jdv.19162"},{"key":"180601","doi-asserted-by":"crossref","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 2020;396:110-20.","DOI":"10.1016\/S0140-6736(20)30609-7"},{"key":"180602","unstructured":"Cervelli V, De Angelis B, Balzani A, et al. Treatment of stable vitiligo by ReCell system. Acta Dermatovenerol Croat 2009;17:273-8."},{"key":"180603","unstructured":"Cervelli V, Spallone D, Lucarini L, et al. Treatment of stable vitiligo hands by ReCell system: a preliminary report. Eur Rev Med Pharmacol Sci 2010;14:691-4."},{"key":"180604","doi-asserted-by":"crossref","unstructured":"Mulekar SV, Ghwish B, Al Issa A, Al Eisa A. Treatment of vitiligo lesions by ReCell vs. conventional melanocyte-keratinocyte transplantation: a pilot study. Br J Dermatol 2008;158:45-9.","DOI":"10.1111\/j.1365-2133.2007.08216.x"},{"key":"180605","doi-asserted-by":"crossref","unstructured":"Salloum A, Bazzi N, Maalouf D, Habre M. Microneedling in vitiligo: A systematic review. Dermatol Ther 2020;33:e14297.","DOI":"10.1111\/dth.14297"},{"key":"180606","doi-asserted-by":"crossref","unstructured":"Atefi N, Ziaeifar E, Seirafianpour F, et al. Evaluation of efficacy and safety of vitiligo treatment with micro-needling combined with N-Acetylcysteine and micro-needling alone: A double-blinded randomized controlled clinical trial. J Cosmet Dermatol 2024;23:2220-30.","DOI":"10.1111\/jocd.16274"},{"key":"180607","doi-asserted-by":"crossref","unstructured":"Konstantinova VA, Olisova OY, Gladko VV, Burova EP. Vitiligo - new treatment approach. Clin Cosmet Investig Dermatol 2019;12:911-7.","DOI":"10.2147\/CCID.S229175"},{"key":"180608","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4.","DOI":"10.1001\/jama.2013.281053"},{"key":"180609","doi-asserted-by":"crossref","unstructured":"Sun, Xiu-kun, Sheng, An-qi, Xu, Ai-e, Tofacitinib for the treatment of refractory progressive vitiligo: a retrospective case series. Dermatol Ther 2024,9944826.","DOI":"10.1155\/2024\/9944826"},{"key":"180610","doi-asserted-by":"crossref","unstructured":"Maghfour J, Hamzavi IH, Mohammad TF. An updated review on systemic and targeted therapies for vitiligo. Dermatol Rev 2022;3:313-25.","DOI":"10.1002\/der2.166"}],"container-title":["European Journal of Translational Myology"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/bam\/article\/download\/13787\/13112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/bam\/article\/download\/13787\/13657","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/bam\/article\/download\/13787\/13112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:48:50Z","timestamp":1768466930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/bam\/article\/view\/13787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.4081\/ejtm.2025.13787","relation":{},"ISSN":["2037-7460","2037-7452"],"issn-type":[{"value":"2037-7460","type":"electronic"},{"value":"2037-7452","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,26]]}}}